Activated charcoal forms non-IgE binding complexes with peanut proteins


      Background: Conventional management of peanut-induced anaphylaxis is composed of administration of epinephrine, antihistamine, and steroid and stabilization of airway, ventilatory, and circulatory function. Therapies directed toward slowing or preventing further absorption of peanut protein from the gastrointestinal tract after accidental ingestion have not been a routine part of management. Objective: The purpose of this study was to determine the ability of activated charcoal to complex with peanut protein, thereby preventing its binding to either peanut-specific IgE or peanut-specific IgG. Methods: Peanut protein was coincubated with micronized activated charcoal suspension at pH 3.5 or 7.4. Peanut protein complexed with charcoal was removed by centrifugation. Binding of residual peanut protein to peanut-specific IgG was measured by a sandwich ELISA assay. Also, ability of uncomplexed peanut protein to bind to peanut-specific IgE was determined by Western blot and by skin prick testing in subjects with peanut allergy. Results: Activated charcoal (AC) formed complexes with peanut protein, effectively competing for binding with peanut-specific IgG in a sandwich ELISA assay. AC complexed efficiently with peanut protein at both neutral and acidic pH in as little as 60 seconds. AC was also able to remove IgE-binding peanut allergens from solution as determined by Western blot and by skin prick testing in subjects with peanut allergy. A ratio of 200 mg of AC to 1 mg peanut protein was required for complete removal of peanut protein from solution. AC was able to complex with peanut protein within food matrices such as ice cream and chocolate. Conclusion: The data presented herein show that AC removes both IgE-binding and IgG-binding peanut proteins from solution rapidly at both neutral and acidic pH. These data suggest that administration of AC may be useful as an adjunct to slow or to prevent further absorption of peanut protein from the gastrointestinal tract after accidental ingestion by individuals with peanut allergy. (J Allergy Clin Immunol 2003;112:175-9.)



      TBS (Tris-buffered saline), TTBS (TBs with 0.1% Tween 20)
      To read this article in full you will need to make a payment


        • Krenzelok EP
        • Leikin JB
        Approach to the poisoned patient.
        Dis Mon. 1996; 42: 509-607
        • Nelson HS
        • Lahr J
        • Rule R
        • Bock A
        • Leung D
        Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract.
        J Allergy Clin Immunol. 1997; 99: 44-51
        • Bowden CA
        • Krenzelok EP
        Clinical applications of commonly used contemporary antidotes: a US perspective.
        Drug Saf. 1997; 16: 9-47
        • Manoguerra AS
        Gastrointestinal decontamination after poisoning: where is the science?.
        Crit Care Clin. 1997; 13: 709-725
        • American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists Study Group
        Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning.
        J Toxicol Clin Toxicol. 1999; 37: 731-751
        • Lapatto-Reiniluoto O
        • Kivisto KT
        • Neuvonen PJ
        Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram.
        Br J Clin Pharmacol. 1999; 48: 148-153
        • Laine K
        • Kivisto KT
        • Pelttari S
        • Neuvonen PJ
        The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration.
        Pharmacol Toxicol. 1996; 79: 270-273
        • Gittelman MA
        • Stephan M
        • Perry H
        Acute pediatric digoxin ingestion.
        Pediatr Emerg Care. 1999; 15: 359-362
        • Rance F
        • Dutau G
        Peanut hypersensitivity in children.
        Pediatr Pulmonol Suppl. 1999; 18: 165-167
        • Clarke McKilburn SA
        • Hourihane JO
        • Dean KR
        • Warner JO
        • Dean TP
        Serological characteristics of peanut allergy.
        Clin Exp Allergy. 1998; 28: 1251-1257
        • Hourihane JO
        Peanut allergy: current status and future challenges.
        J Clin Exp Allergy. 1997; 27: 1240-1246
        • Sicherer SH
        • Munoz-Furlong A
        • Burks AW
        • Sampson HA
        Prevalence of peanut and tree nut allergy in the US determined by a random dial telephone survey.
        J Allergy Clin Immunol. 1999; 103: 559-562
        • Nordlee JA
        • Taylor SL
        • Jones RT
        • Yuninger JW
        Allergenicity of various peanut products as determined by RAST inhibition.
        J Allergy Clin Immunol. 1981; 68: 376-382
        • Bradford MM
        A refined and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
        Anal Biochem. 1976; 72: 248-254
        • Laemmli UK
        Cleavage of structural proteins during assembly of the head of bacteriophage T4.
        Nature. 1970; 227: 680-685
        • Hourihane JO
        • Kilburn SA
        • Nordlee JA
        • Hefle SL
        • Taylor SL
        • Warner JO
        An evaluation of the sensitivity of subjects with peanut allergy to very low doses of peanut protein: a randomized, double-blind, placebo-controlled food challenge study.
        J Allergy Clin Immunol. 1997; 100: 596-600
        • Crockett R
        • Krishel SJ
        • Manoguerra A
        • Williams SR
        • Clark RF
        Prehospital use of activated charcoal: a pilot study.
        J Emerg Med. 1996; 14: 335-338
        • Allison TB
        • Gough JE
        • Brown LH
        • Thomas SH
        Potential time savings by prehospital administration of activated charcoal.
        Prehosp Emerg Care. 1997; 1: 73-75